Company Peptonic Medical AB Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
|
05-31 | Peptonic Medical Secures European Patent for Treatment of Vulvodynia | MT |
05-31 | Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch | CI |
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Self-diagnostic Rapid Tests and Self-care Treatments
100.0
%
| 44 | 100.0 % | 37 | 100.0 % | -14.93% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 44 | 100.0 % | 37 | 100.0 % | -14.93% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Erik Sundquist
CEO | Chief Executive Officer | 54 | 13/04/21 |
Hadar Kessary
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | 64 | 31/12/08 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Tarek Shoeb
BRD | Director/Board Member | 55 | 23/05/23 |
Karl Blom
BRD | Director/Board Member | 55 | - |
Anders Norling
BRD | Director/Board Member | 58 | 23/05/22 |
Daniel Rudeklint
DFI | Director of Finance/CFO | 43 | - |
Anna Stinger
BRD | Director/Board Member | - | 23/05/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 7,677,766,800 | 114,705,799 ( 1.494 %) | 0 | 1.494 % |
Company contact information
Peptonic Medical AB
Gustavslundsvägen 143
167 51, Bromma
+46 8 53 02 01 10
http://www.peptonicmedical.se![address Peptonic Medical AB](https://cdn.zonebourse.com/static/address/23249821.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B |
- Stock Market
- Equities
- PMED Stock
- Stock
- Company Peptonic Medical AB